Catalyst Pharmaceutical CPRX Operating Expense
Operating Expense at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept cprx:OperatingExpense.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's operating expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's operating expense?
- Catalyst Pharmaceutical (CPRX) reported operating expense of $76.16M in Q1 2026.
- How has Catalyst Pharmaceutical's operating expense changed year-over-year?
- Catalyst Pharmaceutical's operating expense decreased by 2.4% year-over-year, from $78.05M to $76.16M.
- What is the long-term trend for Catalyst Pharmaceutical's operating expense?
- Over 4 years (2021 to 2025), Catalyst Pharmaceutical's operating expense has grown at a 39.1% compound annual growth rate (CAGR), from $88.45M to $331.21M.
- What does operating expense mean?
- This metric aggregates all costs incurred in the normal course of business operations, including research and development, selling, general, and administrative expenses. It serves as a comprehensive measure of the company's cost structure required to support drug development, commercialization, and corporate overhead. Analyzing this figure relative to revenue provides insight into the company's operational leverage and cost management efficiency.